Now enables identification of allergens at the molecular level
MIAMI--(Business Wire)--
Today at the 2009 Annual Meeting of the American College of Allergy, Asthma &
Immunology, Phadia US introduced two new products designed specifically to meet
the unique needs of the nation`s 6,000 allergists. ImmunoCAP ISAC and ImmunoCAP
HR are new offerings designed to augment traditional allergy testing
methodologies and enable diagnosis of complex food allergies at the molecular
level, available through its own PiRL testing facility.
Immuno Solid-phase Allergy Chip, or ISAC, is a multi-array technology package
designed to provide a detailed assessment of specific allergies as part of the
initial patient assessment and workup. With ISAC, allergists can test for the
particular molecular components driving the allergic disease process in
patients. As a result, allergists can identify precisely those patients in
danger of severe allergic reaction to allergens such as peanut, wheat, or egg
and many others.
ISAC uses a small sample of blood to produce results for 103 components
representing a wide spectrum of allergens. With this additional information, the
allergist can then identify the unique sensitization patterns for every patient,
enabling the development of a personalized allergy management plan.
In addition to the technology announced above, Phadia is proud to announce the
availability of ImmunoCAP HR, utilizing proven ImmunoCAP solid phase technology.
ImmunoCAP HR provides Highly Refined specific allergen component testing so that
doctors can assess a patients` relative risk for allergy symptoms through better
characterization of the precise quantitation of specific IgE antibodies to
various allergen components. With this technology, clinicians will be able to
define the patient`s sensitization to specific allergen components.
David Esposito, President of Phadia US says, "Food allergies are some of the
most difficult to diagnose, and create confusion and sometimes even hysteria
with patients. With ISAC and Highly Refined components, Phadia brings
personalized medicine to allergy and immunology specialists and provides the
specialty community with a new set of diagnostic tools to complement traditional
testing methodologies. Allergists can use component testing to further refine
the allergic profile of their patients with a variety of allergies, identify
cross-reactive allergies, and counsel for targeted exposure reduction."
ImmunoCAP ISAC and ImmunoCAP HR are offered in the United States through the
Phadia Immunology Reference Laboratory (PiRL). Phadia is introducing these
exciting new technologies at the Annual Meeting of the American College of
Allergy, Asthma & Immunology, in Miami. Mr. Esposito added, "This is an
opportunity for allergists attending the Annual Meeting to learn about ISAC
first-hand in order to better understand how this exciting new information can
complement their existing practice."
Mr. Esposito continued, "Molecular-level diagnostics represents true
next-generation technology in the complex field of allergy diagnosis and
treatment. We look forward to bringing this technology to the specialist
community with ISAC and ImmunoCAP HR."
About Phadia
Phadia AB, headquartered in Uppsala, Sweden, is a global specialty diagnostics
company and the world leader in in vitro allergy and autoimmunity diagnostics
research and product development. Its US affiliate, Phadia US, Inc. is in
Portage, Michigan. For more information, contact their US Customer Service at
800.346.4364.
For more information on Phadia or ImmunoCAP, please visit
http://www.isitallergy.com/.
Gregory FCA Communications
Joseph Crivelli
610-228-2100 (office)
Copyright Business Wire 2009
